Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Cell Res. 2023 Feb;33(2):131-146. doi: 10.1038/s41422-022-00755-2. Epub 2023 Jan 6.
Members of the tumor necrosis factor receptor superfamily (TNFRSF) are important therapeutic targets that can be activated to induce death of cancer cells or stimulate proliferation of immune cells. Although it has long been implicated that these receptors assemble preligand associated states that are required for dominant interference in human disease, such states have so far eluded structural characterization. Here, we find that the ectodomain of death receptor 5 (DR5-ECD), a representative member of TNFRSF, can specifically self-associate when anchored to lipid bilayer, and we report this self-association structure determined by nuclear magnetic resonance (NMR). Unexpectedly, two non-overlapping interaction interfaces are identified that could propagate to higher-order clusters. Structure-guided mutagenesis indicates that the observed preligand association structure is represented on DR5-expressing cells. The DR5 preligand association serves an autoinhibitory role as single-domain antibodies (sdAbs) that partially dissociate the preligand cluster can sensitize the receptor to its ligand TRAIL and even induce substantial receptor signaling in the absence of TRAIL. Unlike most agonistic antibodies that require multivalent binding to aggregate receptors for activation, these agonistic sdAbs are monovalent and act specifically on an oligomeric, autoinhibitory configuration of the receptor. Our data indicate that receptors such as DR5 can form structurally defined preclusters incompatible with signaling and that true agonists should disrupt the preligand cluster while converting it to signaling-productive cluster. This mechanism enhances our understanding of a long-standing question in TNFRSF signaling and suggests a new opportunity for developing agonistic molecules by targeting receptor preligand clustering.
肿瘤坏死因子受体超家族(TNFRSF)的成员是重要的治疗靶点,可以被激活以诱导癌细胞死亡或刺激免疫细胞增殖。尽管长期以来一直暗示这些受体组装预先结合的状态,这些状态对于人类疾病中的主要干扰是必需的,但这些状态迄今仍未得到结构表征。在这里,我们发现死亡受体 5(DR5-ECD)的胞外结构域,作为 TNFRSF 的代表性成员,当锚定在脂质双层时可以特异性地自我缔合,并且我们报告了通过核磁共振(NMR)确定的这种自缔合结构。出乎意料的是,确定了两个不重叠的相互作用界面,这些界面可以扩展到更高阶的簇。结构指导的突变表明,在表达 DR5 的细胞上观察到的预先结合的关联结构得到了体现。DR5 的预先结合起到了自动抑制作用,部分分离预先结合的簇的单域抗体(sdAbs)可以使受体对其配体 TRAIL 敏感,甚至在没有 TRAIL 的情况下诱导大量受体信号。与需要多价结合以聚集受体进行激活的大多数激动性抗体不同,这些激动性 sdAbs 是单价的,并且特异性作用于受体的寡聚、自动抑制构象。我们的数据表明,像 DR5 这样的受体可以形成与信号传导不兼容的结构定义的预簇,而真正的激动剂应该破坏预先结合的簇,同时将其转化为具有信号产生能力的簇。该机制增强了我们对 TNFRSF 信号传导中长期存在的问题的理解,并为通过靶向受体预先结合聚类来开发激动性分子提供了新的机会。